TP53 and breast carcinoma: On the other hand, a missense mutant version of p53 in breast cancer cells can inhibit ferroptosis by interacting with the transcription factor NRF2, the master regulator of the antioxidant response; this interaction causes the selective activation and repression of NRF2 target genes and promotes survival of breast cancer cells in an oxidative stress inducing microenvironment, which would otherwise be deadly to these cells [42].